Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial.
Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial.
复制标题
安非他酮临床试验中多巴胺转运蛋白和受体多态性对戒烟的影响。
DOI：
10.1037/0278-6133.22.5.541
复制
发表时间：
2003
期刊：
影响因子：
--
通讯作者：
Epstein,LeonardH
中科院分区：
文献类型：
--
作者：
Lerman,Caryn;Shields,PeterG;Wileyto,EPaul;Audrain,Janet;HawkJr,LarryH;Pinto,Angela;Kucharski,Susan;Krishnan,Shiva;Niaura,Ray;Epstein,LeonardH
本研究在安慰剂对照临床试验中检测多巴胺能基因在预期戒烟和安非他酮治疗反应中的作用。欧洲血统的吸烟者（N= 418）提供血液样本进行遗传分析，并接受安非他酮或安慰剂（10周）加咨询。评估包括多巴胺D2受体（DRD2）基因型，多巴胺转运蛋白（SLC6A3）基因型，人口统计学因素和尼古丁依赖。在治疗结束（EOT）和6个月随访时验证吸烟状态。结果提供了证据，证明DRD 2 × SLC 6A3对延长戒烟时间和EOT时至复发时间具有显著的相互作用效应，与治疗条件无关。然而，在6个月随访时，这些影响不再显著。这些结果提供了来自前瞻性临床试验的第一个证据，即改变多巴胺功能的基因可能会影响治疗阶段的戒烟和复吸。（PsycInfo数据库记录（c）2016阿帕，保留所有权利）
This study examined the role of dopaminergic genes in prospective smoking cessation and response to bupropion treatment in a placebo-controlled clinical trial. Smokers of European ancestry (N= 418) provided blood samples for genetic analysis and received either bupropion or placebo (10 weeks) plus counseling. Assessments included the dopamine D2 receptor (DRD2) genotype, dopamine transporter (SLC6A3) genotype, demographic factors, and nicotine dependence. Smoking status was verified at the end of treatment (EOT) and at 6-month follow-up. The results provided evidence for a significant DRD2× SLC6A3 interaction effect on prolonged smoking abstinence and time to relapse at EOT, independent of treatment condition. Such effects were no longer significant at 6-month follow-up, however. These results provide the first evidence from a prospective clinical trial that genes that alter dopamine function may influence smoking cessation and relapse during the treatment phase.(PsycINFO Database Record (c) 2016 APA, all rights reserved)